Literature DB >> 35372905

Safety of Gadolinium-Based Contrast Agents in Patients with Stage 4 and 5 Chronic Kidney Disease: a Radiologist's Perspective.

Erik V Soloff1, Carolyn L Wang1.   

Abstract

Entities:  

Keywords:  Chronic Kidney Disease; Gadolinium; chronic kidney disease; gadolinium deposition; gadolinium-based contrast agent; nephrogenic systemic fibrosis; radiology

Mesh：

Substances：

Year:  2020        PMID： 35372905      PMCID： PMC8809096          DOI： 10.34067/KID.0000502019

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  36 in total

Review 1.  Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.

Authors:  Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian van der Pol; Swapnil Hiremath
Journal:  Can Assoc Radiol J       Date:  2018-05       Impact factor: 2.248

2.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

3.  Self-reported gadolinium toxicity: A survey of patients with chronic symptoms.

Authors:  Lauren M B Burke; Miguel Ramalho; Mamdoh AlObaidy; Emily Chang; Michael Jay; Richard C Semelka
Journal:  Magn Reson Imaging       Date:  2016-05-19       Impact factor: 2.546

Review 4.  Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.

Authors:  Dragan Stojanov; Aleksandra Aracki-Trenkic; Daniela Benedeto-Stojanov
Journal:  Neuroradiology       Date:  2016-02-12       Impact factor: 2.804

Review 5.  Nephrogenic systemic fibrosis and management of high-risk patients.

Authors:  Ersan Altun; Richard C Semelka; Ceylan Cakit
Journal:  Acad Radiol       Date:  2009-04-17       Impact factor: 3.173

6.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

7.  Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI).

Authors:  Tatjana Seute; Pieter Leffers; Guul P M ten Velde; Albert Twijnstra
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

Review 8.  Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency.

Authors:  Elena Ledneva; Svetlana Karie; Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

Review 9.  Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview.

Authors:  Anna Falk Delgado; Danielle Van Westen; Markus Nilsson; Linda Knutsson; Pia C Sundgren; Elna-Marie Larsson; Alberto Falk Delgado
Journal:  Insights Imaging       Date:  2019-08-23

10.  Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

Authors:  Gilbert Deray; Olivier Rouviere; Lorenzo Bacigalupo; Bart Maes; Thierry Hannedouche; François Vrtovsnik; Claire Rigothier; Jean-Marie Billiouw; Paolo Campioni; Joaquin Ferreiros; Daniel Devos; Daniel Alison; François Glowacki; Jean-Jacques Boffa; Luis Marti-Bonmati
Journal:  Eur Radiol       Date:  2012-12-05       Impact factor: 5.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.